Crystalline forms of an RSK inhibitor

US12378245B2 · kind B2 · utility

Assignee

• PHOENIX MOLECULAR DESIGNS · CA

Inventors

• Richard Winnike · Woodbine, US
• Elaine McPherson · Edinburgh, GB
• Erik Flahive · San Diego, US
• Sandra Dunn · Richmond, CA
• Jonathan James Loughrey · Penicuik, GB

Key dates

• Filing date: Feb 10, 2020
• Grant date: Aug 5, 2025
• Expiry date: Jul 3, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4 -yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido [3′,2′: 4,5]-pyrrolo [1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I).